Discussion
SARS-CoV-2 infection
ADVERSE EVENTS, SARS-COV-2 INFECTION
We observed that there is no difference in SARS-CoV-2 infection incidence between the group that received HCQ prophylaxis and the control group. Despite the low statistical power of our study, this finding aligns with other trials evaluating the effectiveness of HCQ to prevent SARS-CoV-2 infection or treat COVID-19 [At the beginning of the pandemic, a call was made for well-designed, robust trials to combat the growing number of observational studies and anecdotal evidence that hinted at the benefits of HCQ. Among the first published, a trial on post-exposure (within 4 days) HCQ prophylaxis found no difference in the incidence of illness compatible with COVID-19 [Fortunately, the trials did not report an increase in serious adverse events, in particular cardiac, associated with the use of HCQ [Within the first 100 days of the pandemic, a vast number of trials had already been registered on ClinicalTrials.gov and the World Health Organization Inter- national Clinical Registry Platform [